Evidence map›Paper›PMID 35403253›Full record

ArticleJournal of food biochemistry2022

Controlled modulation of all the arms of the immunity including innate immunity by biological response modifier glucans, a simple yet potential nutritional supplement strategy to fight COVID-19.

Nobunao Ikewaki, Gene Kurosawa, Tomohiko Kisaka, Samuel J K Abraham

Open access · greenAbstract read
In one paragraph

Article in Journal of food biochemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Trial
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 3 countries.

Nobunao IkewakiDepartment of Medical Life Science, Kyushu University of Health and Welfare, Nobeoka, Japan.
Gene KurosawaDepartment of Academic Research Support Promotion Facility, Center for Research Promotion and Support, Fujita Health University, Toyoake, Japan.
Tomohiko KisakaBio Design Division, Translational Research Center, Hiroshima University, Hiroshima, Japan.
Samuel J K AbrahamThe Mary-Yoshio Translational Hexagon (MYTH), Nichi-In Centre for Regenerative Medicine (NCRM), Chennai, India.ORCID 0000-0003-2646-2687
Fujita Health University · JPHiroshima University · JPKyushu University of Health and Welfare · JPSaint Xavier University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune modulation, being one of the potential strategies to combat COVID-19 infection, emphasis has been laid on enhancing the innate immune response in a balanced manner. Beta (β)-glucans have been suggested as nonspecific immunostimulatory adjuvants to beneficially boost protective antiviral immunity. Through this article, we wish to emphasize that β-glucans not only enhance the innate immunity but also possess the capability to modulate all the arms of the immunity viz., innate, adaptive, TRIM at different sites including those postulated to be the entry site of the SARS-CoV2. Other than immune modulation capabilities, the beneficial metabolic- and coagulation-related effects of β-glucans, a simple nutritional supplementation strategy, make them be considered for larger clinical studies to validate their prophylactic vaccine adjuvant and nutritional-based therapeutic supplement activities to effectively fight the COVID-19 pandemic. PRACTICAL APPLICATIONS: A 360° wholesome protection from viral infections is possible only when all the arms of the immune system function in a balanced and effective manner which is especially important in COVID-19. Nutritional supplementation using biological response modifier beta (β)-glucans (BRMGs) is worth considering for large-scale clinical studies based on their track record of safety and their beneficial regulation of all the arms of the immune system.

Indexed as

beta-GlucansCOVID-19Adjuvants, ImmunologicDietary SupplementsGlucansHumansImmunity, InnatePandemicsRNA, ViralSARS-CoV-2Adjuvants, Immunologicbeta-GlucansGlucansRNA, Viralantiviralbeta (β)-glucansCOVID-19immune modulationinnate immunity

Identifiers

PMID35403253
PMCPMC9114898
OpenAlexW4223435020

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.